Barlogie B, Crowley J. Prognostic implications of cumulative dosing in total therapy 3. Blood. 2012;120(16):3383-3385.

On page 3385 in the 18 October 2012 issue, there are errors in the first author’s conflict-of-interest disclosure. The originally published disclosure reads as shown.

Conflict-of-interest disclosure: B.B. has received research funding from Celgene, Novartis. Centocor, Johnson and Johnson, Onyx, and ICON; is a consultant to Celgene, Millenium, and Genzyme; and has received speaking honoraria from Celgene and Millennium. He is a coinventor on patents and patent applications related to the use of GEP in cancer medicine and holds interest in Signal Genetics. The remaining author declares no competing financial interests.

The disclosure should have read as shown.

Conflict-of-interest disclosure: B.B. has received research funding from Celgene and Millennium; is a consultant to Celgene and Millennium; and is a coinventor on patents and patent applications related to the use of GEP in cancer medicine that have been licensed to Myeloma Health, LLC. The remaining author declares no competing financial interests.

National Institutes of Health